Drug Profile
RZL 012
Alternative Names: RZL-012Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Raziel Therapeutics
- Developer Raziel Therapeutics; Yissum Research Development Company
- Class Carbazoles; Obesity therapies; Small molecules; Thermogenics
- Mechanism of Action Lipolysis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adiposis dolorosa; Obesity
- Phase I/II Subcutaneous fat disorders
- No development reported Lipoedema
Most Recent Events
- 20 Oct 2023 Raziel Therapeutics completes a phase II trial in Obesity in USA (SC) (NCT05763160)
- 15 Jun 2023 Raziel Therapeutics completes a phase I/II trial in Subcutaneous fat disorders (In volunteers) in USA (NCT05466448)
- 12 Jun 2023 Raziel Therapeutics completes a phase I trial in Obesity (In volunteers) in the US (Injection) (NCT05476679)